1408282-26-7Relevant articles and documents
Copper-Mediated Radiosynthesis of [18F]Rucaparib
Chen, Zijun,Destro, Gianluca,Guibbal, Florian,Chan, Chung Ying,Cornelissen, Bart,Gouverneur, Véronique
supporting information, p. 7290 - 7294 (2021/09/14)
The poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib is used in the clinic to treat BRCA-mutated cancers. Herein, we report two strategies to access the 18F-isotopologue of rucaparib by applying a copper-mediated nucleophilic 18F-fluorodeboronation. The most successful approach features an aldehydic boronic ester precursor that is subjected to reductive amination post-18F-labeling and affords [18F]rucaparib with an activity yield of 11% ± 3% (n = 3) and a molar activity (Am) up to 30 GBq/μmol. Preliminary in vitro studies are presented.
ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS
-
Page/Page column 136, (2020/11/30)
The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
CRYSTALLINE OF CAMPHORSULFONIC ACID SALT OF RUCAPARIB AND METHOD OF PREPARING OF TRICYCLIC COMPOUNDS, RUCAPARIB AND CRYSTALLINE OF CAMPHORSULFONIC ACID SALT OF RUCAPARIB
-
, (2020/06/15)
A method of preparing a tricyclic compound of formula (I), comprising the step of converting a compound of formula (II) into a compound of formula (III); and hydrogenating the compound of formula (III) in the presence of hydrogenation catalyst and hydrogen to form the tricyclic compound of formula (I); wherein R1 is H or a C1-3 alkyl group; and R2 is H, a halogen element or a C1-3 alkyl group.
For treating ovarian cancer drug Rucaparib intermediate preparation method (by machine translation)
-
Paragraph 0057; 0075-0077; 0081; 0093-0095; 0097; 0109-0112, (2019/04/17)
The invention discloses a method for treating ovarian cancer drug Rucaparib intermediate preparation method, comprises the following steps: the compound of formula III with the amino compound in the acetaldehyde dibasically condensing agent or a carboxylic acid activating agent under the action of the condensation reaction, the compound of formula IV; type IV compounds under the action of the acid and reducing agent, the compound of formula V, i.e. the drug Rucaparib intermediate. Preparation method of the invention, route is reasonable in design, avoiding the nitration reaction, avoid the use of a large number of strong acid, and ensuring the safe production, safety and environmental protection; the reaction conditions are mild and easy to control, effectively shortening the reaction route, shortens the reaction cycle, the production cost is reduced, and is suitable for industrial production. (by machine translation)
Synthetic method of azepino [5,4, 3-cd] indole-6-ketone compound
-
, (2019/04/30)
The invention relates to synthetic method of an azepino [5,4, 3-cd] indole-6-one compound, specifically, the invention discloses a preparation method of a compound of formula IA, and the method comprises the following steps: reacting a compound of formula II with a compound of formula III through a Grandberg reaction to prepare the compound of the IA. The method disclosed by the invention has theadvantages that raw materials are cheap and easily available, reaction steps are short, the yield is high, and the method is suitable for industrial production.
Preparation method of Ruikapabu midbody
-
Paragraph 0027-0030; 0032; 0034, (2019/01/22)
The invention discloses a preparation method of a Ruikapabu midbody, comprising the following steps: adding 2-ethyl nitroacetate, methylbenzene and p-tert-Butylcatechol into a compound 1 to perform nucleophilic substitution and reduction ring closing reaction, so as to obtain a compound 2, and enabling the compound 2 to generate oxidization reaction, to obtain 8-fluorine-1, 3, 4, 5-tetrahydrogen-azepine [5, 4, 3-CD] indole-6-ketone, wherein R is any one of the following radicals: alkyl, benzyl or phenyl. The preparation method is less in reaction steps, easy in operation and high in yield in the reaction step; is mild in reaction condition, does not need anhydrous and anaerobic operation, also does not need high temperature and high pressure, and is high in safety; the production process disclosed by the invention can realize industrialization, can perform production of hundreds of kilograms, and can ensure relatively high product yield.
Preparation method of key intermediate 1408282-26-7 of ovarian cancer resisting drug Rucaparib
-
Paragraph 0040; 0046; 0047; 0053; 0054; 0060, (2018/11/22)
The invention discloses a preparation method of a key intermediate 1408282-26-7 of an ovarian cancer resisting drug Rucaparib, and relates to preparation of medical intermediates. The preparation method comprises the following steps: reacting a compound 1 with potassium nitrate to obtain a compound 2; reacting the compound 2 with trimethylsilylacetylene to obtain a compound 3; reacting the compound 3 with hydrogen to obtain a compound 4; carrying out self cyclization on the compound 4 to obtain a compound 5; reacting the compound 5 with nitroethylene to obtain a compound 6; reacting the compound 6 with the hydrogen to obtain the key intermediate 1408282-26-7 of the ovarian cancer resisting drug Rucaparib. The method has the advantages that nitro-sulfuric acid mixed nitration reaction and the discharge of wastewater and waste gas are avoided, safe production is ensured, and safety and environment friendliness are realized; raw materials are easy to obtain and low in price and cost, thereby facilitating industrial production; the reaction yield is greatly improved, the reaction route is optimized, the product purification steps are simplified and the industrial production is facilitated.
Poly(ADP-ribose) Polymerase in Neurodegeneration: Radiosynthesis and Radioligand Binding in ARC-SWE tg Mice
Alluri, Santosh R.,Riss, Patrick J.
, p. 1259 - 1263 (2018/06/26)
We report the synthesis, radiosynthesis, and characterization of a radioligand for poly(ADP-ribose) polymerase (PARP). PARP is of central importance in cell homeostasis, neuroplasticity, and neurodegeneration in the brain. A radiolabeled PARP inhibitor was developed and used for autoradiographic quantification of PARP protein concentration in wild-type and transgenic rodent brains ex vivo in high resolution. The binding of [3H]rucaparib was found to be confined to PARP-expressing domains, for example, cerebellar cortex or hippocampal regions in both models. Saturation binding experiments confirmed selective and reversible binding to a single site (Kd = 1.1 ± 0.2 nM).
Preparation method of intermediate of drug Rucaparib treating ovarian cancer
-
Paragraph 0065; 0066; 0067; 0068; 0069; 0070; 0071-0075, (2017/07/20)
The invention discloses a preparation method of an intermediate of drug Rucaparib treating ovarian cancer. The preparation method comprises the following steps: 1) in the presence of protective gas and inorganic alkali, stirring 3-fluoro-5-trifylmethyl benzoate with (1-diazo-2-oxo--cyan propyl) dimethylphosphonate to react to obtain a mixture M; 2) stirring the mixture M obtained I the step 1) in an acidic condition to react to obtain 3-cyanoethyl-6-fluoro-1H-indole-4-methyl formate; and 3) performing palladium -carbon catalytic hydrogenation on the product obtained in the step 2) in the acidic condition to obtain the intermediate 8-fluoro-1,3,4,5-tetrahydro[5,4,3-cd] indoe-6-one. According to the method disclosed by the invention, a target compound is high in yield and purity; the method is mild in condition, relatively few in step, short in reaction time and more suitable for industrial production.
Method for preparing key intermediate of ovarian cancer-resistant medicine Rucaparib
-
, (2017/04/18)
The invention discloses a method for preparing a key intermediate of an ovarian cancer-resistant medicine Rucaparib. The method is characterized by comprising the following steps: a compound S-1 reacts with NCS to obtain a compound S-2; the compound S-2 reacts with vinylmagnesium bromide to obtain a compound S-3; the compound S-3 reacts with thionyl chloride to obtain a compound S-4; the compound S-4 is dissolved in DMF and then reacts with phosphorus oxychloride to obtain a compound S-5; nitromethane and ammonium acetate are added into the compound S-5 to react to obtain a compound S-6; and the compound S-6 reacts with hydrogen at normal temperature to obtain the key intermediate of the ovarian cancer-resistant medicine Rucaparib. According to the method, nitration is avoided, the safety risk in the production process is reduced, and the method is safe and environmentally friendly; raw materials are easy to obtain and low in cost, and the production cost is effectively reduced; reaction routes are effectively reduced, and the method saves time and labor and greatly improves reaction efficiency.